This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

3 Industries and 3 Stocks Riding a 2012 M&A Boom

Stocks in this article: IDIX HUN TYC TEL ABB TNB INHX EMN SOA

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

3. Biotech and Idenix Pharmaceuticals

It was a roller coaster January for hepatitis C drugmakers after Bristol-Meyers Squibb (BMY) bid $2.5 billion for Inhibitex (INHX), launching a Hep C "deal-a-palooza" that pushed competitor shares higher.

After the deal, investors focused on whether other independent drug makers with Hep C drugs in development could be targets to a larger industry player looking add drugs as others go generic. While Achillion Pharmaceuticals (ACHN) emerged as another possible takeover candidate, analysts and investors focused on Idenix Pharmaceuticals (IDIX).

Idenix Pharmaceuticals may be the next hepatitis C acquisition in the biotech space after the Inhibitex deal, according to a research note published by Wedbush research analyst Duane Nash. There was plenty of pent up demand for Inhibitex, which received 5 competing bids to go with Bristol-Meyers Squibb's winning offer, according to a regulatory filing.

At a January industry luncheon discussing hepatitis C drug development, a poll by ISI Group biotech analyst Mark Schoenebaum of 120 participants showed that Idenix Pharmaceuticals had a greater than 50% chance of being acquired.

The size of the commercial opportunity for new all-oral Hep C treatment regimens is a much-debated topic, with many seeing big sales numbers. Forty eight percent of the investors at the January meeting predicted worldwide Hep C drug sales between $8 billion and $10 billion by 2019.

Idenix Pharmaceuticals shares surged on Bristol Meyers Squibb's Inhibitex purchase, which was cut at a 163% premium to the company's share price prior to the deal announcement. However in February, Idenix shares dropped from post-crisis highs earlier after results from a competing hepatitis C treatment by Gilead Sciences (GILD) raised questions about the need for Idenix's IDX-184 drug in development.

Other potential deals in the healthcare sector include a potential takeover of clinical research providers Covance (CVD) and Charles River Laboratories (CRL), according to a February research note from Sterne Agee analyst Greg Bolan. Jefferies analysts also pointed to Wuxi PharmaTech (WX) as a potential private equity target.

In Roche's hostile offer for Illumina, investors bid the genetic sequencing machinery maker's shares far higher than the $73 offer price after large cap healthcare equipment makers like Siemens Healthcare (SI), Johnson & Johnson (JNJ), Abbott Laboratories (ABT) and Becton, Dickinson (BDX) emerged as competing bidders according to analysts.

Nevertheless, even after deal announcements there are still risks for investors betting on M&A in the healthcare and pharmaceutical space. In January, Valeant Pharmaceuticals (VRX) withdrew its hostile $7.5 a share offer for ISTA Pharmaceuticals (ISTA) after making little progress on takeover negotiations. A mega-merger between Express Scripts (ESRX) and Medco Health Solutions (MHS) could still be iced on antitrust scrutiny.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,308.60 -78.61 -0.45%
S&P 500 2,022.56 -6.99 -0.34%
NASDAQ 4,686.1350 +4.6380 0.10%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs